Invited review
The urokinase plasminogen activator system as a novel target for tumour therapy

https://doi.org/10.1054/fipr.2000.0079Get rights and content

Abstract

Substantial data have been collected for numerous types of solid cancer, including cancer of the breast, the gastrointestinal and urological tract, the lung, and the brain, demonstrating a strong clinical value of the plasminogen activation system in predicting disease recurrence and survival in cancer patients. Elevated levels of certain members of the plasminogen activation system, the serine protease uPA (urokinase-type plasminogen activator), its receptor (uPA-R; CD87), and inhibitor (PAI-1), in tumour tissue or blood emphasize their fundamental role in tumour invasion and metastasis and provide the rationale for novel therapeutic strategies. uPA, besides its proteolytic action toward the extracellular matrix, in concert with uPA-R, PAI-1, and integrins contributes to tumour cell proliferation, adhesion, and migration. Several technical methods of affecting tumour growth and metastasis by targeting the uPA-system in cancer patients at the gene and protein level have been explored: (1) antisense oligodeoxynucleotides to uPA, uPA-R, or PAI-1; (2) antisense oligonucleotides to signal transduction pathway components such as Rel (NF-κ B), affecting uPA but not PAI-1 synthesis; (3) viral vectors delivering genes for components of the plasminogen activation system; (4) soluble, recombinant uPA-R as a scavenger for uPA; (5) monoclonal antibodies directed to uPA or uPA-R blocking uPA/uPA-R interaction; (6) enzymatically inactive uPA to compete for active uPA binding to uPA-R; (7) linear and cyclic uPA-derived peptides to block uPA/uPA-R interaction; (8) toxins, coupled to uPA or fractions thereof to kill tumour cells; (9) naturally occurring inhibitors to uPA and its derivatives for inhibition of uPA proteolytic activity; and (10) synthetic inhibitors to uPA to inhibit uPA proteolytic activity. There is substantial hope that substances designed to affect or turn off the plasminogen activation system will eventually be administered to cancer patients thereby opening a new vista for tumour biology-based, individualized cancer therapy.

References (181)

  • M. Yebra et al.

    Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction

    Exp Cell Res 1999 Jul, 10;

    (1999)
  • M.T. Masucci et al.

    The receptor for human urokinase: a potential target for anti-invasive and anti-metastatic therapy

    Thromb Res Suppl

    (1990)
  • M. Conese et al.

    The urokinase/urokinase-receptor system and cancer invasion

    Baillieres Clin Haematol

    (1995)
  • F. Fazioli et al.

    Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?

    Trends Pharmacol Sci

    (1994)
  • A.M. Sharp et al.

    The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion

    Structure

    (1999)
  • S.J. Harrop et al.

    The crystal structure of plasminogen activator inhibitor 2 at 2.0 A resolution: implications for serpin function

    Structure Fold Des

    (1999)
  • A. Noel et al.

    Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1

    Fibrinolysis & Proteolysis

    (1999)
  • F. Blasi

    uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways?

    Immunol Today

    (1997)
  • M. Yebra et al.

    Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration

    J Biol Chem

    (1996)
  • H. Gardsvoll et al.

    Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries

    FEBS Letters

    (1998)
  • S.H. Ke et al.

    Optimal subsite occupancy and design of a selective inhibitor of urokinase

    J Biol Chem

    (1997)
  • B. Muehlenweg et al.

    Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1-derived synthetic peptides

    Thromb Res

    (2000)
  • E. Appella et al.

    The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases

    J Biol Chem

    (1987)
  • U. Reuning et al.

    Multifunctional potential of the plasminogen activation system in tumour invasion and metastasis (review)

    Int J Oncol

    (1998)
  • M. Schmitt et al.

    Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy

    Thromb Haemost

    (1997)
  • M.J. Duffy

    Cancer metastasis: biological and clinical aspects

    Ir J Med Sci

    (1998)
  • P.A. Andreasen et al.

    The urokinase-type plasminogen activator system in cancer metastasis: a review

    Int J Cancer

    (1997)
  • M. Schmitt et al.

    Tumor-associated proteases

    Fibrinolysis

    (1992)
  • A. Estreicher et al.

    The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes

    J Cell Biol

    (1990)
  • J.D. Vassalli et al.

    A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase

    J Cell Biol

    (1985)
  • J.D. Vassalli et al.

    The plasminogen activator/plasmin system

    J Clin Invest

    (1991)
  • M. Ploug

    Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site

    Biochemistry

    (1998)
  • M. Ploug et al.

    Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor

    Biochemistry

    (1994)
  • N. Chucholowski et al.

    Flow cytofluorometry in tumour cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA)

    Biochem Soc Trans

    (1992)
  • R.W. Stephens et al.

    The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

    Breast Cancer Res Treat

    (1998)
  • N. Behrendt et al.

    The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface

    Biol Chem Hoppe Seyler

    (1995)
  • A. Nykjaer et al.

    Recycling of the urokinase receptor upon internalization of the uPA: serpin complexes

    EMBO J

    (1997)
  • P. Ragno et al.

    Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface

    Eur J Biochem

    (1995)
  • M.V. Carriero et al.

    Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer

    Cancer Res

    (1999)
  • M. Germer et al.

    Kinetic analysis of integrin-dependent cell adhesion on vitronectin-the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides

    Eur J Biochem

    (1998)
  • J. Bohuslav et al.

    Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes

    J Exp Med

    (1995)
  • P. Carmeliet et al.

    Gene targeting and gene transfer studies of the biological role of the plasminogen/ plasmin system

    Thrombosis Haemostasis

    (1995)
  • P. Carmeliet et al.

    Physiological consequences of loss of plasminogen activator gene function in mice

    Nature

    (1994)
  • J. Romer et al.

    Impaired wound healing in mice with a disrupted plasminogen gene

    Nature Medicine

    (1996)
  • J.C. Kirchheimer et al.

    Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme

    Eur J Biochem

    (1989)
  • J.C. Kirchheimer et al.

    Proliferation of a human epidermal tumor cell line stimulated by urokinase

    FASEB J

    (1987)
  • J.C. Kirchheimer et al.

    Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line

    Proc Natl Acad Sci USA

    (1989)
  • T. Luther et al.

    Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue

    Am J Pathol

    (1997)
  • S.M. Kanse et al.

    Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders

    Arterioscler Thromb Vasc Biol

    (1997)
  • N. Busso et al.

    Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells

    J Cell Biol

    (1994)
  • Cited by (128)

    • Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA)

      2012, Bioorganic and Medicinal Chemistry
      Citation Excerpt :

      An amidine based, peptide-derived inhibitor (1, Fig. 1) reduces the number of experimental lung metastases in a fibrosarcoma model in mice,12 and two clinical phase I trials with uPA inhibitors 2a (WX-UK1)13 and its prodrug 2b (WX-671 or MESUPRON®) have been successfully completed. Moreover, compound 2b showed favorable results in randomized phase II trial in patients with locally advanced nonmetastatic pancreatic cancer and phase II trial in patients with HER2-negative metastatic breast cancer (MBC) has been initiated.14 Wendt et al. reported a series of substituted naphthamidines as inhibitors of uPA (3a–c as representative examples) and 3c was shown to possess high selectivity towards tPA, thrombin and plasmin.15

    • Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of serpinE1 and serpinB2 in cancer

      2011, Journal of Biological Chemistry
      Citation Excerpt :

      very low density lipoprotein receptor Combined tumor overexpression of uPA, its receptor (uPAR), and SerpinE1 (serine protease inhibitor E1) is strongly correlated with poor patient prognosis (1–3) and metastatic potential (4–8). Consequently, uPA and SerpinE1 expression is recommended as an independent prognostic indicator in node-negative breast cancer (9).

    • Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients

      2009, Gynecologic Oncology
      Citation Excerpt :

      uPA is strongly implicated as a promoter of tumor progression in various human malignancies, and is synthesized and secreted as a pro-enzyme. uPA is activated by binding with high affinity specific membrane-bound or soluble cell surface uPA receptors (uPAR), which efficiently convert plasminogen, into plasmin, that directly or indirectly cleaves ECM components [5]. Plasmin can also activate latent elastase and matrix metalloproteinases (MMPs), which can also degrade ECM components [6].

    View all citing articles on Scopus
    View full text